title: Zolmitriptan: differences from sumatriptan.
abstract: Zolmitriptan is a potent 5-HT(1B/1D) agonist whose targets include the peripheral and central components of the trigeminovascular system. It is generally well-tolerated and has dose-dependent efficacy in the treatment of migraine. The 2.5 mg dose is felt to provide the best balance between efficacy and adverse events. In a direct comparative study, the 2 h headache response rate for zolmitriptan 2.5 mg was statistically superior to sumatriptan 25 and 50 mg, although at 3.3% not clinically significant. Two comparative studies have found no difference in adverse event frequency between zolmitriptan and sumatriptan.
authors.affiliation: Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. peterg@ion.ucl.ac.uk
authors.forename: P J
authors.initials: PJ
authors.lastname: Goadsby
authors.forename: C J
authors.initials: CJ
authors.lastname: Boes
mesh_terms: D003027:Cluster Headache / Q000188:drug therapy; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D023303:Oxazolidinones / Q000627:therapeutic use*; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D018170:Sumatriptan / Q000627:therapeutic use*; D014363:Tryptamines
chemical_list: D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan; D018170:Sumatriptan